evipedia.ai
← Back

Ibutamoren Mesylate for Health & Longevity

Evidence Review created on 09/10/2026 using AI4L / Opus 5

Also known as: MK-677, MK-0677, Ibutamoren, Nutrobal, LUM-201

Motivation

Ibutamoren mesylate is an oral compound that prompts the body to release more of its own growth hormone. It was built to copy ghrelin, the stomach hormone that signals hunger and also triggers growth hormone release. Because growth hormone output falls steadily from early adulthood onward, and because muscle and bone decline alongside it, a compound that restores youthful output without injections has an obvious draw.

A pharmaceutical company developed the compound in the 1990s and carried it into large trials in older adults recovering from hip fracture and in people with memory loss. Development was later halted and it never reached the market. It has since circulated widely through online sellers, marketed to people building muscle or hoping to slow physical decline, despite having no approved use anywhere.

This review examines what the human trials actually measured, how the reported gains in body composition sit against the changes in blood sugar and other markers, and how raising a growth signal squares with evidence that lower levels of that same signal track with longer life.

Benefits - Risks - Protocol - Conclusion

High-level overviews of ibutamoren mesylate and the growth hormone secretagogue class (compounds that prompt the body to release more of its own growth hormone), drawn from expert commentary and non-systematic academic literature.

Only one priority platform yielded usable content. Chris Kresser, Life Extension and Lifespan.io site searches returned no article on this compound or on growth hormone secretagogues. Peter Attia and Rhonda Patrick have each covered it, but both items sit behind a premium membership wall, so neither can be link-verified for a reader and neither is listed.

Grokipedia

Ibutamoren

Provides the pharmacological identity, development history and doping-control status in one place, including the receptor binding data and the anti-doping cases that clinical sources do not cover.

Examine

Ibutamoren

Grades the compound against outcomes rather than biomarkers, and is unusually direct that the biomarker shifts have not produced strength or function gains and do not persist after discontinuation.

ConsumerLab

No ConsumerLab article on ibutamoren mesylate exists. A direct site search returned only Recalls & Warnings notices about consumer products found to contain it as an undeclared ingredient, not a page about the compound itself.

ConsumerLab tests dietary supplements. Ibutamoren mesylate is an unapproved investigational drug that is not lawful as a supplement ingredient, so it falls outside the site’s review scope, as prescription medications do.

Systematic Reviews

No systematic reviews or meta-analyses for Ibutamoren Mesylate were found on PubMed as of September 10, 2026.

Neither side of the trade-off is represented: there is no systematic review of the claimed anabolic benefit, and none of the principal risk of impaired glucose handling.

Mechanism of Action

Ibutamoren mesylate is a non-peptide agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a, the receptor that the hunger hormone ghrelin normally activates). It was engineered to be orally active and selective for that receptor rather than the growth hormone-releasing hormone receptor (GHRH receptor, the separate switch the brain normally uses), which signals by a different route. Occupying GHS-R1a on somatotrophs (the pituitary cells that make growth hormone) and on neurons of the hypothalamus activates a phospholipase C cascade (an enzyme chain that raises calcium inside the cell), amplifying existing growth hormone pulses instead of imposing a flat elevation. Restraint by somatostatin (the brain’s braking signal on growth hormone) and feedback from insulin-like growth factor 1 (IGF-1, the liver-made growth factor that carries out most growth hormone effects) stay intact, so peaks remain nearer the physiological range. The same receptor in hypothalamic appetite centers drives hunger, and receptor activity in sleep circuits accompanies the reported shifts in deep and rapid eye movement (REM) sleep.

It is a small molecule with high oral bioavailability, peak plasma levels at one to two hours, and a plasma half-life most often reported at four to six hours, though some human analyses cite figures near 24 hours. Clearance is hepatic, principally via CYP3A4 (a liver enzyme that breaks down many drugs). Distribution spans pituitary, hypothalamus and peripheral receptor-bearing tissue.

Two mechanistic readings compete: that restoring pulsatile growth hormone reverses age-related tissue loss, or that reduced signaling through the same axis is itself protective.

Historical Context & Evolution

The compound’s ancestry begins with the growth hormone-releasing peptides made in Cyril Bowers’ laboratory from 1977, opiate analogues that unexpectedly released growth hormone from pituitary cells. Those peptides were unusable as medicines: growth hormone-releasing peptide-6 had roughly 0.3% oral bioavailability and a 20-minute half-life. Merck screened non-peptide compounds against that template, reaching L-692,429 and then L-163,191, which entered development as MK-0677, or ibutamoren mesylate (Smith, 2005).

The original intent was replacement therapy: growth hormone deficiency in children and adults, and the wasting of serious illness. Interest widened to health optimization once trials showed that once-daily oral administration returned insulin-like growth factor 1 in adults aged 64 to 81 to the young-adult range (Chapman et al., 1996).

Nearly the entire trial record was generated by Merck Research Laboratories, the compound’s owner, and the current program by Lumos Pharma — a direct financial interest in the compound’s adoption that applies to the favorable body-composition findings and the null cognitive and functional findings alike. Merck’s registration path closed when the hip-fracture and sarcopenia (age-related loss of muscle mass and strength) programs failed to convert hormone changes into function, and a 563-patient Alzheimer’s trial found no clinical effect (Sevigny et al., 2008). The molecule then re-emerged through unregulated online vendors, while its licensed form returned to pediatric growth hormone deficiency trials.

Expected Benefits

High 🟩 🟩 🟩

Restored Growth Hormone Pulsatility and IGF-1 Levels

The compound amplifies existing growth hormone pulses and lifts insulin-like growth factor 1 into the range typical of healthy young adults. This is the most replicated finding in the literature, reproduced in randomized controlled trials (RCTs, studies in which participants are randomly assigned to drug or placebo) in healthy older adults, obese men, dialysis patients and people with Alzheimer’s disease, and sustained for twelve months without fading. It is a marker of drug action rather than an outcome: in the largest trial, clear target engagement produced no cognitive benefit.

Magnitude: 25 mg daily raised mean 24-hour growth hormone concentration by 97 ± 23% and IGF-1 from 141 ± 21 to 265 ± 29 µg/L over four weeks in adults aged 64–81 (Chapman et al., 1996); a 12-month trial recorded a 72.9% rise (Sevigny et al., 2008) and a dialysis crossover trial a 65% rise over placebo (Campbell et al., 2018).

Increased Fat-Free Mass

Fat-free mass rises and keeps rising while treatment continues, driven by growth hormone’s opposition to protein breakdown and by IGF-1 signaling in muscle. Two placebo-controlled trials measured it by dual-energy X-ray absorptiometry (DXA, a body-composition scan), one over two years in healthy older adults and one over eight weeks in obese men. The nuance is decisive here: limb fat rose alongside lean mass, total weight rose more than lean mass did, and the extra tissue produced no measurable gain in strength or function.

Magnitude: Fat-free mass changed by +1.1 kg (95% confidence interval [CI, the range in which the true value most likely lies] 0.7 to 1.5) versus −0.5 kg (CI −1.1 to 0.2) on placebo over 12 months, with body weight rising 2.7 kg versus 0.8 kg (Nass et al., 2008); an 8-week trial in obese men found a significant DXA fat-free-mass gain (Svensson et al., 1998).

Medium 🟩 🟩

Increased Femoral-Neck Bone Mineral Density Alongside Alendronate

Growth hormone stimulates bone-building cells, so pairing a secretagogue with a drug that blocks bone breakdown was expected to preserve the formation the blocker suppresses. An 18-month RCT in 292 osteoporotic women aged 64–85 confirmed the mechanism and produced a bone mineral density (BMD, how much mineral is packed into bone) gain at the femoral neck, but at no other site. The authors flagged that a single-site gain weighed against the hormonal adverse effects is a weak case. Bone turnover markers rise on the compound alone, without a density gain.

Magnitude: Femoral-neck BMD rose 4.2% on the combination versus 2.5% on alendronate alone (p < 0.05), with no advantage at lumbar spine, total hip or total body (Murphy et al., 2001). Osteocalcin (a bone-formation marker) rose 29.4% and urinary N-telopeptide (a bone-breakdown marker) 22.6% on the compound alone (Murphy et al., 1999).

Improved Sleep Architecture

Deep sleep and growth hormone release share regulatory machinery, so a secretagogue given at bedtime plausibly shifts sleep stages. A placebo-controlled crossover trial measured this directly in eight young men over seven days and six adults aged 65–71 over fourteen days. The sample is small and the endpoint is a laboratory sleep recording rather than reported sleep quality, but the direction was consistent in both age groups and the frequency of abnormal sleep patterns fell sharply. No later trial has attempted replication in a healthy longevity-oriented population.

Magnitude: At 25 mg, stage IV sleep duration rose roughly 50% and REM sleep more than 20% in young men, in whom deviations from normal sleep fell from 42% to 8%; in older adults REM rose nearly 50% with shortened REM latency and deviations from normal sleep also declined (Copinschi et al., 1997).

Low 🟩

Preserved Nitrogen Balance During Caloric Restriction

Seven days of treatment reversed the protein loss induced by an 18 kcal/kg diet in eight healthy volunteers. The crossover design is sound but the trial is very small, one week long, and nitrogen balance is a laboratory measure rather than a preserved-function outcome (Murphy et al., 1998).

Magnitude: Mean daily nitrogen balance was +0.31 ± 0.21 g/day on treatment versus −1.48 ± 0.21 g/day on placebo (p < 0.01) during the second week of restriction.

Improved Low-Density to High-Density Lipoprotein Cholesterol Ratio ⚠️ Conflicted

Eight weeks of treatment lowered the ratio of low-density to high-density lipoprotein cholesterol in obese men, but the component changes were transient, and a two-year trial found only a small fall against baseline with no between-group difference. Net reading: a favorable lipid signal exists but does not survive between groups.

Magnitude: The ratio fell significantly at 8 weeks (p < 0.05 versus placebo), with the apolipoprotein A-I and high-density lipoprotein changes already gone by then (Svensson et al., 1999); the two-year trial recorded −5.4 mg/dL low-density lipoprotein against baseline only (Nass et al., 2008).

Faster Gait Speed After Hip Fracture ⚠️ Conflicted

One phase IIb trial found faster gait speed and fewer falls; a larger, longer trial in the same population found no functional gain despite a comparable hormone response. Net reading: functional benefit after hip fracture is unproven, and the positive trial was stopped early on safety grounds.

Magnitude: Gait speed differed by 0.7 score units (CI 0.17 to 1.28; p = 0.011) with stair-climbing power unchanged (Adunsky et al., 2011); no functional measure reached significance in the 161-patient trial (Bach et al., 2004).

Speculative 🟨

Direct Antitumor Signaling Through MDM2–p53

Laboratory work suggests the molecule binds MDM2, the enzyme that degrades the tumor-suppressor protein p53, reducing viability only in cancer lines with an intact pathway. The basis is in-vitro and computational modeling alone.

Benefit-Modifying Factors

  • Baseline growth hormone reserve: In growth hormone-deficient adults the growth hormone response tracked baseline output (r = 0.81, p = 0.009), so the least deficient responded most (Chapman et al., 1997). An intact pituitary is a prerequisite, not an optional extra.

  • Baseline IGF-1 level: Trials targeting a metabolic effect have enrolled only people below the third quartile of age-adjusted IGF-1, on the reasoning that those already in the upper range have little headroom and inherit the risks without the gain.

  • Genetic polymorphisms: Variants in GHSR and GHRL (the genes encoding the ghrelin receptor and ghrelin itself) alter receptor signaling, and the exon-3-deleted growth hormone receptor variant increases sensitivity to growth hormone. Neither has been tested prospectively as a response predictor here.

  • Sex and hormonal status: The two-year trial stratified women by whether they were receiving hormone replacement, because oral estrogen blunts the liver’s conversion of growth hormone into IGF-1. Women on oral estrogen show a smaller rise at the same dose.

  • Body composition and adiposity: Obesity suppresses growth hormone secretion at baseline, so absolute gains in fat-free mass were demonstrable in obese men within eight weeks, while total and visceral fat did not fall — the anabolic signal is not a fat-loss signal.

  • Pre-existing conditions: Impaired glucose handling, heart failure and active malignancy all convert an already modest benefit into a poor exchange, because each is aggravated by exactly the hormonal changes the compound produces.

  • Age at initiation: Benefit is largest where the age-related fall in growth hormone is largest, which pushes the plausible window into the seventh decade and beyond — precisely the group in which the heart-failure and glucose signals were observed.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Impaired Glucose Tolerance and Reduced Insulin Sensitivity

Growth hormone directly antagonizes insulin action, so glucose control worsens as a matter of pharmacology rather than idiosyncrasy. This is the most consistent adverse finding, appearing in healthy older adults, growth hormone-deficient adults, obese men, hip-fracture patients and Alzheimer’s patients. In obese men fasting values held steady while an oral glucose tolerance test showed impairment at two and eight weeks, so fasting glucose alone under-detects it. The effect is dose-related and reverses on discontinuation, but it runs against the metabolic targets this audience optimizes.

Magnitude: Fasting glucose rose from 5.4 ± 0.3 to 6.8 ± 0.4 mmol/L at four weeks on 25 mg (p < 0.01) (Chapman et al., 1996); over two years fasting glucose rose 0.3 mmol/L (5 mg/dL, p = 0.015) with falling insulin sensitivity and rising HbA1c (average blood sugar over about three months) (Nass et al., 2008); raised glucose affected 15.4% versus 4.6% on placebo over 12 months (Sevigny et al., 2008).

Increased Appetite

Ghrelin receptor activation in the hypothalamus drives food intake, which is the intended effect in wasting states and an unwanted one in anyone managing energy balance. It was the only adverse event significantly more common than placebo in the two-year trial, and it is the mechanism by which the compound reliably adds total body weight rather than lean weight alone. It typically attenuates over some months but not in everyone, and bedtime dosing can convert it into night-time hunger.

Magnitude: Reported by 29 of 43 participants (67%) on treatment versus 8 of 22 (36%) on placebo (p = 0.02) over two years (Nass et al., 2008); the class effect on energy intake is documented across ghrelin receptor agonists (Sigalos & Pastuszak, 2018).

Fluid Retention, Peripheral Edema and Musculoskeletal Pain

Growth hormone promotes sodium and water retention, producing lower-limb swelling, joint and muscle aching, and occasionally carpal-tunnel-type numbness — the same cluster seen with recombinant growth hormone. In the two-year trial these were described as transient and mild, but they are the commonest reason for dose reduction in practice. Severity tracks dose, and they resolve on withdrawal. Because they arrive early while body-composition change arrives late, they dominate the first months of exposure.

Magnitude: Mild transient edema affected 19 of 43 participants (44%) on treatment versus 6 of 22 (27%) on placebo, and transient muscle pain 14 of 43 (33%) versus 2 of 22 (9%), neither difference reaching significance over 12 months (Nass et al., 2008); the same cluster is catalogued as a recognized class effect (Sigalos & Pastuszak, 2018).

Medium 🟥 🟥

Congestive Heart Failure Signal in Frail Older Adults ⚠️ Conflicted

A phase IIb trial in hip-fracture patients was terminated early after more cases of congestive heart failure appeared on treatment, plausibly through fluid retention on an already strained heart. A larger trial in the same population found no such excess, and baseline blood pressure was higher in the treated arm of the positive trial, so confounding is possible. The regulator nonetheless cites this as its central safety objection. Net reading: unresolved, and the only signal that has stopped a trial.

Magnitude: Congestive heart failure occurred in 4 of 62 treated patients (6.5%) versus 1 of 61 on placebo (1.7%), with adverse events in 77% versus 55% (Adunsky et al., 2011); serious events were evenly distributed in the comparator trial (Bach et al., 2004).

Raised Cortisol and Prolactin ⚠️ Conflicted

The receptor is expressed in pituitary lactotrophs (the cells that make prolactin), and the compound has some activity on the stress axis, so both hormones can drift upward. Trials disagree: cortisol rose over two years but was unchanged in shorter studies with intensive 24-hour sampling, while prolactin rose modestly in several. Net reading: prolactin rises reproducibly but stays within reference range, while the cortisol finding is confined to long-term exposure.

Magnitude: Cortisol rose 47 nmol/L (CI 28 to 71) over two years (p = 0.020) (Nass et al., 2008); prolactin rose 23% within the normal range while cortisol was unchanged at four weeks (Chapman et al., 1996), and 24-hour cortisol profiles were unaffected at seven days (Copinschi et al., 1996).

Low 🟥

Drug-Induced Liver Injury

A healthy man in his thirties developed transaminitis (raised liver enzymes) after two months of use, resolving on withdrawal (Cobani et al., 2025). A self-administration report recorded alanine aminotransferase (ALT, a liver enzyme released when liver cells are damaged) rising 205%, with a second compound co-administered (Cardaci et al., 2022).

Magnitude: Alanine aminotransferase rose 205% above baseline in the self-administration report, resolving after withdrawal. No controlled trial has reported hepatotoxicity as an outcome, so no incidence figure exists.

Adulterated and Mislabeled Consumer Products

Products sold as performance supplements have been found to contain the compound undeclared, alongside undisclosed testosterone, estradiol and growth hormone. One such product produced gynecomastia (breast tissue growth in men) and suppressed gonadal function, both reversible on cessation (Chong et al., 2024).

Magnitude: Not quantified in available studies. Contamination rates in the unregulated market have never been measured systematically, so the evidence is confined to case reports and regulatory warning letters.

Speculative 🟨

Long-Term Cancer Risk from Sustained IGF-1 Elevation ⚠️ Conflicted

Sustained IGF-1 elevation is linked to cancer incidence, yet a systematic review of ghrelin-receptor agonists found mostly null or inverse associations (Sever et al., 2016). Net: no human outcome data on this compound resolve it.

Risk-Modifying Factors

  • Baseline glucose status: Anyone with fasting glucose above roughly 100 mg/dL, HbA1c at or above 5.7%, or a family history of type 2 diabetes starts closer to the threshold that the compound’s insulin antagonism will push them across.

  • Cardiac reserve: The heart-failure signal appeared in frail, recently fractured, older patients, not in healthy volunteers. Existing ventricular dysfunction, uncontrolled hypertension or valvular disease converts routine fluid retention into a clinically meaningful load.

  • Sex-based differences: Women taking oral estrogen show a blunted IGF-1 rise, which reduces both benefit and hormone-mediated risk at a given dose. Men appear more prone to noticeable edema, plausibly through greater lean mass and sodium retention.

  • Genetic polymorphisms: CYP3A4 (the liver enzyme clearing the drug) activity varies widely between individuals, and the exon-3-deleted growth hormone receptor variant amplifies downstream signaling. Neither has been characterized prospectively here, so exposure at a fixed dose is unpredictable.

  • Pre-existing conditions: Active or prior malignancy, untreated proliferative diabetic retinopathy, obstructive sleep apnea and cirrhosis each align with a distinct hazard — growth signaling, retinal proliferation, soft-tissue swelling and impaired clearance respectively.

  • Age: Older users carry more of the risk. Both the heart-failure signal and the largest glucose excursions were recorded in adults over 65, the same group in whom the lean-mass benefit is largest.

  • Concurrent compound use: The gravest documented biochemical derangements occurred when it was self-administered alongside androgen receptor modulators, which independently damage lipids, liver enzymes and gonadal function.

Key Interactions & Contraindications

  • Insulin and insulin secretagogues (glimepiride, glipizide, gliclazide): Caution; the compound’s insulin antagonism erodes glycemic control and can unmask hyperglycemia. Weekly fasting glucose across the first month is the conventional safeguard, and the diabetes regimen typically comes under upward dose pressure.

  • Systemic glucocorticoids (prednisone, dexamethasone): Caution; additive hyperglycemia and additive fluid retention. Where both are unavoidable, separating the courses in time is preferable to concurrent use.

  • Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice): Caution; reduced clearance raises exposure and amplifies edema, appetite and glucose effects. A dose reduction of roughly half is the conventional response.

  • Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St John’s wort): Caution; accelerated clearance can abolish the IGF-1 response, producing an apparent non-response at a normal dose.

  • Other growth hormone secretagogues and GHRH analogues (sermorelin, tesamorelin, ipamorelin, CJC-1295): Caution; additive, and synergistic where the two receptor pathways differ. Stacking multiplies the glucose and fluid-retention burden without an established efficacy gain.

  • Recombinant growth hormone: Absolute contraindication to concurrent use; exogenous hormone bypasses the feedback restraint that is this compound’s only safety advantage, risking supraphysiological exposure.

  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs such as ibuprofen and naproxen): Caution; additive sodium and water retention worsens peripheral edema and blood pressure. Acetaminophen is the neutral alternative for incidental analgesia.

  • Over-the-counter niacin at gram doses: Caution; independently raises fasting glucose and insulin resistance, compounding the principal metabolic risk.

  • Glucose-lowering supplements (berberine, chromium picolinate, alpha-lipoic acid): Monitor; opposing rather than additive. They can mask a rising glucose trend on laboratory testing without removing the underlying insulin resistance.

  • Melatonin and sedating sleep aids: Caution; the compound already alters sleep staging, and layering sedatives obscures whether a sleep change is benefit or adverse effect.

Populations who should avoid Ibutamoren Mesylate:

  • Active malignancy, or any cancer treated within the past 5 years
  • Heart failure of New York Heart Association (NYHA) Class III or IV, or ejection fraction below 40%
  • Type 2 diabetes, or HbA1c at or above 6.5%
  • Untreated proliferative diabetic retinopathy
  • Hepatic impairment of Child-Pugh Class B or C
  • Pregnancy and lactation
  • Untreated moderate-to-severe obstructive sleep apnea (apnea-hypopnea index above 15)
  • Competitive athletes subject to World Anti-Doping Agency (WADA) or military testing, and serving military personnel
  • Adolescents with open epiphyses (growth plates not yet fused) outside a supervised trial

Risk Mitigation Strategies

  • Sub-trial starting dose with titration: Beginning at 10 mg once daily and moving to 25 mg only after 4 weeks of stable glucose limits the early edema, appetite and insulin-resistance load that drives most discontinuations.

  • Baseline glucose screening: A baseline fasting glucose, HbA1c and 2-hour oral glucose tolerance test detects the impairment that fasting values alone miss, and excludes anyone already at or above 5.7% HbA1c from the principal metabolic risk.

  • Glucose recheck at 4 and 12 weeks: The hormonal response plateaus by 4 weeks, so this is when insulin resistance becomes measurable. A fasting glucose rise above 10 mg/dL or HbA1c above 5.7% triggers dose reduction or cessation.

  • Capped IGF-1 target: Titrating to the upper half of the age-adjusted reference range rather than the maximum tolerated dose limits the sustained growth-signal exposure behind the theoretical cancer concern and much of the fluid retention.

  • Cardiac screening above age 65: Blood pressure, an NT-proBNP measurement (a blood marker of heart strain) and a symptom review before starting address the congestive heart failure signal that stopped one trial in exactly this population.

  • Daily weight and ankle circumference tracking: A gain above 2 kg in the first month, or visible ankle swelling, identifies fluid retention early enough to halve the dose before it becomes a cardiac load.

  • Prior age-appropriate malignancy screening: Colonoscopy, skin examination and sex-specific screening before starting address the concern that sustained growth signaling accelerates an existing occult tumor rather than initiating one.

  • Batch certificate of analysis: Independent mass-spectrometry identity and purity testing on the specific lot addresses the documented contamination of unregulated products with undisclosed hormones.

  • No stacking with androgen receptor modulators: The severest reported derangements of liver enzymes, lipids and gonadal hormones all involved co-administration; single-agent use removes that compounding.

Therapeutic Protocol

  • Trial-derived standard: 25 mg orally once daily, the dose used in every pivotal RCT and the starting dose recommended in the principal narrative review (Sigalos & Pastuszak, 2018).

  • Lower-dose alternative: 10–12.5 mg daily is widely used in practice to trade a smaller IGF-1 rise for less edema and glucose disturbance. It has never been formally compared against 25 mg.

  • Best time of day: The University of Virginia and Brussels groups dosed at bedtime to align the growth hormone pulse with sleep. Morning dosing is the competing approach, chosen to keep appetite stimulation out of the night.

  • Half-life: Roughly 4–6 hours by most reports, but the IGF-1 elevation persists near 24 hours, which is what makes once-daily administration sufficient.

  • Single versus split dosing: Every controlled trial used a single daily dose. Splitting has no evidence behind it and risks flattening the pulsatile pattern that distinguishes this class from injected growth hormone.

  • Genetic polymorphisms: CYP3A4 activity governs exposure, and the exon-3-deleted growth hormone receptor variant amplifies response. Neither is routinely genotyped, so titration to measured IGF-1 substitutes for pharmacogenetic dosing.

  • Sex-based differences: Women on oral estrogen need either a higher dose or acceptance of a smaller IGF-1 rise, because oral estrogen suppresses hepatic conversion of growth hormone.

  • Age-related considerations: Adults over 70 show the largest hormone response and carry the heart-failure and glucose signals, so protocols in this group start at 10 mg with monthly rather than quarterly review.

  • Baseline biomarker targeting: Trials have restricted entry to those below the third quartile of age-adjusted IGF-1, and titration targets the upper half of the reference range rather than a fixed milligram dose.

  • Pre-existing conditions: Obesity blunts baseline growth hormone and therefore enlarges the measurable response; impaired renal function raises IGF-1 disproportionately at a standard dose (Campbell et al., 2018).

Discontinuation & Cycling

  • Duration of use: Not a short course. The lean-mass change required 12 months to reach its full extent, so any regimen shorter than that captures the adverse effects while forgoing the only demonstrated benefit.

  • Loss of effect on stopping: Body-composition and hormonal gains do not persist after discontinuation, which makes the realistic alternative indefinite exposure rather than a finite intervention.

  • Withdrawal effects: None documented. Feedback restraint stays intact throughout treatment, and 24-hour cortisol profiles were unchanged in short-term studies, so no adrenal insufficiency has been reported on cessation.

  • Tapering: Not required pharmacologically. A stepwise reduction over 1–2 weeks is nonetheless used to make rebound appetite and the return of baseline sleep architecture easier to distinguish from illness.

  • Cycling: Commonly practiced as 8–12 weeks on and 4 weeks off, on the assumption that receptor sensitivity fades. No trial supports it, and the two-year data show sustained hormone elevation without desensitization, so cycling mainly forfeits the slow-accruing benefit.

Sourcing and Quality

  • Regulatory position first: It is an unapproved investigational drug, unlawful as a dietary supplement ingredient in the United States, and the Food and Drug Administration (FDA) has issued warning letters to sellers. No legitimate consumer supply route exists.

  • Compounding pharmacies: Some compounding pharmacies in the United States and abroad dispense it on prescription, which is the only channel with pharmacy-grade identity control and a documented chain of custody.

  • Unregulated research chemicals: Vendors label product as “for research use only” or with a “Research Facts” panel to sidestep supplement rules. Identity, dose accuracy and contamination are entirely unverified in this channel.

  • What to look for: A lot-specific certificate of analysis from an independent laboratory reporting identity and purity by high-performance liquid chromatography and mass spectrometry, dated to the batch in hand rather than a generic document.

  • Contamination is documented, not theoretical: Products have been recalled after regulatory testing found the compound undeclared, and analyzed performance supplements have contained undisclosed testosterone, estradiol and growth hormone alongside it.

  • Formulation: Marketed as the mesylate salt in capsules and in oral solution. Solutions allow finer dose adjustment for titration; capsules offer better dose reproducibility where no analytical verification is available.

Practical Considerations

  • Time to effect: IGF-1 rises within days and plateaus by about 4 weeks. Appetite and fluid changes appear in the first two weeks. Measurable body-composition change takes 6–12 months.

  • Common pitfall — chasing the biomarker: Titrating to the highest tolerated IGF-1 maximizes the fluid, glucose and growth-signal exposure without evidence that higher levels yield greater functional benefit.

  • Common pitfall — ignoring the glucose trend: Fasting glucose can look stable while an oral glucose tolerance test is already abnormal, so relying on a fasting value alone conceals the principal risk.

  • Common pitfall — stacking: Combining it with androgen receptor modulators, sold together by the same vendors, produced the severest reported liver, lipid and hormonal derangements.

  • Regulatory status: Unapproved for any indication; on the WADA Prohibited List and the Department of Defense (DoD) Prohibited Dietary Supplement Ingredients List. Neither body earns revenue from the prohibition. It holds orphan designation for growth hormone deficiency.

  • Cost and payer incentive: Far cheaper than recombinant growth hormone at tens of thousands of dollars a year, so insurers and health systems have a financial reason to favor an oral secretagogue while its manufacturers have the opposite — a structural bias in guidelines and funding.

Interaction with Foundational Habits

  • Sleep: Direct and bidirectional. Bedtime dosing increases deep and REM sleep in laboratory recordings by aligning the drug-driven growth hormone pulse with the natural nocturnal pulse. The same timing can produce night-time hunger that fragments sleep, so the net effect is individual; a two-week trial of morning versus evening dosing usually resolves it.

  • Nutrition: Potentiating in the wrong direction. The appetite effect raises intake and total body weight, so the lean-mass gain is easily buried under fat gain without a fixed protein target and a defined energy ceiling. Lower-glycemic patterns are the standard pairing, given the insulin resistance the compound induces.

  • Exercise: Indirect and complementary rather than additive. No trial has tested it alongside a resistance program, and the lean tissue it adds produced no strength gain without training. Resistance work supplies the mechanical signal the hormone alone does not, and also opposes the insulin resistance.

  • Stress management: Indirect. Cortisol rose modestly over two years, though shorter studies with 24-hour sampling found no change. Because cortisol and the drug’s glucose effect push the same direction, poor stress control amplifies the metabolic cost; sleep regularity and aerobic work are the practical counterweights.

Monitoring Protocol & Defining Success

Baseline testing precedes the first dose and sets the individual reference against which every later value is read. Because the compound acts on glucose handling, fluid balance and the growth hormone axis at once, a single later value carries little meaning without its own starting point. A baseline panel covers glucose control including a 2-hour oral glucose tolerance test, liver enzymes, lipids, pituitary hormones, blood pressure, body composition and bone density, plus an age-appropriate malignancy screen.

Ongoing monitoring follows the pharmacology rather than the calendar. IGF-1 and fasting glucose are rechecked at 4 weeks, when the hormonal response has plateaued, then at 12 weeks and every 3–6 months thereafter. Liver enzymes, lipids and blood pressure follow the same 3–6 month cadence; body composition and bone density are remeasured every 12 months.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
IGF-1 Upper half of the age-adjusted reference range, not above it Confirms drug effect and caps growth-signal exposure Non-fasting; ranges are assay-specific, so use one laboratory throughout
Fasting glucose 70–85 mg/dL Detects the principal metabolic risk 8–12 hour fast; the conventional reference range runs to 99 mg/dL, well above this target; pair with fasting insulin from the same draw
HbA1c 4.8–5.4% Shows whether a glucose drift is sustained The conventional cut-off is below 5.7%; reflects roughly 3 months; falsely low in anemia or after recent blood loss
2-hour oral glucose tolerance test Below 120 mg/dL at 2 hours Catches impairment while fasting glucose still reads normal 75 g load; the trials that measured it found impairment fasting values missed
Fasting insulin 2–5 µIU/mL Quantifies the insulin resistance behind the glucose rise Conventional reference ranges extend to roughly 25 µIU/mL; draw with fasting glucose to derive HOMA-IR, a calculated index of insulin resistance; target below 1.5
ALT and AST Below 25 U/L (men), below 20 U/L (women) Detects the liver injury seen in case reports Conventional laboratory upper limits are roughly 40 U/L (men) and 33 U/L (women); AST is aspartate aminotransferase, a second liver enzyme; avoid strenuous exercise for 48 hours beforehand
Apolipoprotein B Below 80 mg/dL Tracks whether the lipid picture drifts unfavorably The conventional cut-off is nearer 100 mg/dL; ApoB is apolipoprotein B, the protein carried on every artery-blocking particle; non-fasting is acceptable
Prolactin Within the laboratory reference range Detects the modest rise this class produces Draw mid-morning, at least an hour after waking; stress and nipple stimulation raise it
Morning cortisol 10–15 µg/dL at 08:00 Checks the stress-axis drift reported with long-term use Strongly time-of-day dependent; read with a symptom review, not in isolation
NT-proBNP Below 125 pg/mL Screens the congestive heart failure signal in older users NT-proBNP is a peptide released by a strained heart; it rises with age and renal impairment
Blood pressure Below 120/80 mmHg Fluid retention raises it, and it modified the heart-failure signal Seated, after 5 minutes’ rest; average three readings across a week
Appendicular lean mass by DXA No established target; track change from the individual’s own baseline The only benefit the trials demonstrated Same scanner each time; hydration shifts distort the result
Bone mineral density T-score above −1.0 Growth hormone raises bone turnover in both directions Same scanner and site each time; annual intervals, since change is slow

Qualitative markers matter as much as the panel, because the trials found hormone changes without functional ones:

  • Grip strength and a timed chair-stand, since the trials found lean mass gains without strength gains
  • Perceived recovery between resistance sessions
  • Sleep quality and, separately, whether hunger is waking the individual at night
  • Daytime appetite intensity, and whether it is attenuating over months
  • Visible ankle or finger swelling, and ring or shoe tightness
  • Joint and muscle aching, and any hand numbness or tingling
  • Energy, mood and libido, the last of which prolactin can blunt

Emerging Research

  • Phase 3 pediatric growth hormone deficiency trial: NCT06948214 is recruiting 150 children, comparing annualized height velocity at 12 months against placebo. Sponsored by Lumos Pharma, which owns the compound. A positive result would supply the first regulatory-grade long-term safety dataset the class has had.

  • Muscle preservation during GLP-1 weight loss: NCT07754045 plans to randomize 202 older adults with obesity to the compound plus semaglutide, a GLP-1 drug (glucagon-like peptide-1, a gut hormone that curbs appetite), or semaglutide plus placebo, with the Short Physical Performance Battery (a scored walking, balance and chair-stand test) at week 26 as primary endpoint.

  • Completed liver-fat pilot with posted results: NCT05364684, an open-label study of 25 mg daily in adults with fatty liver, found liver fat rose 3.9 ± 6.7% over six months against 6.6 ± 6.1% in historical controls (p = 0.4), with no gain in inflammation score or liver enzymes.

  • Long-term safety extension: NCT05796440 is following 60 children who completed earlier trials, with treatment-emergent adverse events as the primary endpoint through 2028. Sponsor-run, and the only source of multi-year safety data currently accruing anywhere.

  • Evidence that could weaken the case: Ablating the growth hormone receptor in middle-aged mice extended lifespan in both sexes and protected neuromuscular performance and bone (Duran-Ortiz et al., 2026), and low IGF-1 predicted survival in exceptionally long-lived people (Milman et al., 2014).

  • The unmeasured endpoint: No safety data on malignancy or mortality exist for any growth hormone secretagogue, a gap the principal review names explicitly (Sigalos & Pastuszak, 2018). Until a cohort is followed for decades the longevity question stays open in both directions.

Conclusion

Ibutamoren mesylate does what it was designed to do. Administered orally once daily, it makes the body release more of its own growth hormone and lifts the growth factor it controls into the range seen in healthy young adults, holding that elevation for years without fading. What it has not done, across every study that looked, is convert the hormonal change into something a person can feel. Lean tissue increases, while strength, walking speed and everyday function do not.

Against that sits a consistent cost. Blood sugar control worsens, appetite rises so total weight climbs faster than lean weight, and swelling and aching are common early on. In frail older patients, a heart failure concern stopped one study early, and a second study did not confirm it. Liver injury and contaminated products appear only in isolated reports.

Almost the entire evidence base was produced by the companies that owned or now own the molecule, which shapes both what was studied and what was left unmeasured. Nothing has been measured about cancer or death rates. And the deepest tension is unresolved: the growth signal this compound raises is the same one that, at lower levels, tracks with longer life in both long-lived animals and long-lived people.

Top - Benefits - Risks - Protocol